2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Checkpoint Inhibitor, Workforce, Clinical Practice (Health Services and Quality), Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3587 Target trial emulation of GLP-1RA therapy in Hodgkin and non-Hodgkin lymphoma

Travis Edward Stueber, DO, Omar Farooq Amir, MD2, Dominic Earl Mitchell Jarrett, MD3, Anum Jalil4, Ahmed Bashir Sukhera, MD5, Prashanth Kotla, MD6, Yajur Arya, MD7, Arshi Syal, MD8, Colton Jones, MD, Hematology, Oncologyfellow9, Anand Karnad, MD10
1 UT Health San Antonio, San Antonio, Texas, United States
2 UT Health San Antonio, San Antonio, Texas, United States
3 University of Miami, Miami, Florida, United States
4 UT Health San Antonio, San Antonio, Texas, United States
5 Texas Tech University Health Sciences Center, Lubbock, Texas, United States
6 UT Health San Antonio, San Antonio, Texas, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 UT Health San Antonio, San Antonio, Texas, United States
10 UT Health San Antonio, San Antonio, Texas, United States

Introduction:

Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) account for over 40% of new hematologic malignancies in the United States annually, with 5-year survival rates of approximately 88% and 55-65%, respectively. Concurrent diabetes mellitus, particularly when managed with insulin or characterized by suboptimal glycemic control, is associated with increased treatment complications and inferior survival in patients with cancer. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), increasingly utilized as non-insulin antidiabetic agents, have demonstrated pleiotropic antineoplastic properties in preclinical models, including tumor growth inhibition, enhanced apoptosis, and suppression of angiogenesis. Emerging observational data suggest a mortality benefit associated with GLP-1RA use in select solid malignancies; however, their impact on outcomes in hematologic malignancies remains unexplored. We conducted the first target trial emulation to evaluate the association between GLP-1RA use and overall survival (OS) and remission rates in patients with HL and NHL.

 

Methods:

De-identified data from electronic health records from the TriNetX global federated research network were utilized. Adults (≥18 years) diagnosed with HL or NHL between January 2000 and January 2025 were identified using ICD-10 codes and stratified by GLP-1RA exposure (Cohort A) versus non-exposure (Cohort B). Eligibility required GLP-1RA initiation after lymphoma diagnosis and a documented diagnosis of obesity or type 2 diabetes (T2DM). One-to-one propensity score matching was performed, adjusting for age, sex, race/ethnicity, comorbidities, BMI, HbA1c, lymphoma subtype, and receipt of chemotherapy, immunotherapy, or radiation. The primary endpoint was OS; the secondary endpoint was remission rate, defined by ICD-10 remission codes. Cox proportional hazards regression estimated hazard ratios with 95% confidence intervals for survival and remission. A 3-month landmark analysis was applied to mitigate immortal time bias. Prespecified subgroup analyses assessed outcomes by lymphoma subtype (HL vs. NHL), BMI (≥30 vs. ≤29.9 kg/m²), and diabetic status.

 

Results: 

After propensity score matching, 12,144 patients were included (n=6,072 per cohort). Cohorts were well-balanced: mean age 55 years, 53% female, 73% White, 15% Black, and 8% Hispanic, with a median follow-up of 1,580 days. Despite matching, mean BMI remained higher in the GLP-1RA cohort compared to controls (35 vs. 29 kg/m²; P < 0.001). GLP-1RA use was associated with a significant improvement in overall survival (HR 0.23; 95% CI 0.20–0.26; P = 0.00), corresponding to a 78% reduction in mortality. In contrast, no significant difference in remission rates was observed for either HL (HR 0.75; 95% CI 0.50–1.12; P = 0.15) or NHL (HR 1.16; 95% CI 0.85–1.60; P = 0.36). On subgroup analysis, the survival benefit remained robust and consistent across the following strata: HL (HR 0.19; 95% CI 0.13-0.26, P = 0.00), NHL (HR 0.24; 95% CI 0.21-0.27, P = 0.00), BMI ≤29.9 (HR 0.29; 95% CI 0.24–0.36, P = 0.00), BMI ≥30 (HR 0.23; 95% CI 0.19–0.27, P = 0.00),  T2DM (HR 0.31; 95% CI 0.26–0.36, P = 0.00) and non-diabetic patients (HR 0.19; 95% CI 0.15-0.24, P = 0.00). Notably, the magnitude of benefit was preserved in non-diabetic and non-obese subgroups, suggesting an association effect independent of metabolic indication.

 

Conclusion:

In this target trial emulation study, GLP-1RA use was associated with a 78% reduction in mortality among patients with HL and NHL, with consistent benefit across lymphoma subtypes, BMI categories, and diabetic status, suggesting effects beyond metabolic indication alone. Notably, remission rates did not differ significantly between cohorts. These findings align with emerging evidence of GLP-1RA-associated mortality benefit in solid malignancies and extend this observation to hematologic cancers. Prospective studies with granular treatment and response data are warranted to confirm these associations.

Colton Jones, MD, Hematology, Oncologyfellow: No relevant conflicts of interest to declare.